Responses
E-Poster Presentation
12. SLE treatment
LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
Compose a Response to This Article
Other responses
No responses have been published for this article.